TAKE Solutions Limited (TAKE.NS)
INR 8.0
(-0.37%)
INR 8.0
(-0.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 396.91 Million INR | -72.04% |
| 2022 | 1.41 Billion INR | -73.01% |
| 2021 | 5.25 Billion INR | -28.53% |
| 2020 | 7.35 Billion INR | -52.02% |
| 2019 | 15.33 Billion INR | 24.34% |
| 2018 | 12.33 Billion INR | 33.03% |
| 2017 | 9.27 Billion INR | 133.72% |
| 2016 | 3.96 Billion INR | 25.79% |
| 2015 | 3.15 Billion INR | 36.34% |
| 2014 | 2.31 Billion INR | -52.95% |
| 2013 | 4.91 Billion INR | 8.67% |
| 2012 | 4.52 Billion INR | 34.38% |
| 2011 | 3.36 Billion INR | 290.46% |
| 2010 | 862.22 Million INR | 47.64% |
| 2009 | 584.02 Million INR | 27.34% |
| 2008 | 458.65 Million INR | 69.66% |
| 2007 | 270.33 Million INR | 49.04% |
| 2006 | 181.38 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 62.07 Million INR | -50.19% |
| 2023 Q4 | 207.28 Million INR | 233.95% |
| 2023 FY | 396.91 Million INR | -72.04% |
| 2023 Q1 | 127.29 Million INR | 380.01% |
| 2023 Q2 | 124.61 Million INR | -2.11% |
| 2022 Q4 | 26.51 Million INR | -93.36% |
| 2022 FY | 1.41 Billion INR | -73.01% |
| 2022 Q2 | 544.27 Million INR | 21.09% |
| 2022 Q3 | 399.09 Million INR | -26.67% |
| 2022 Q1 | 449.46 Million INR | -8.69% |
| 2021 Q3 | 1.86 Billion INR | 26.26% |
| 2021 Q4 | 492.25 Million INR | -73.58% |
| 2021 FY | 5.25 Billion INR | -28.53% |
| 2021 Q2 | 1.47 Billion INR | 3.29% |
| 2021 Q1 | 1.42 Billion INR | 21.98% |
| 2020 Q2 | 2.43 Billion INR | 28.13% |
| 2020 Q3 | 1.85 Billion INR | -23.7% |
| 2020 Q4 | 1.17 Billion INR | -36.9% |
| 2020 FY | 7.35 Billion INR | -52.02% |
| 2020 Q1 | 1.89 Billion INR | -52.87% |
| 2019 Q4 | 4.02 Billion INR | -0.88% |
| 2019 Q2 | 3.69 Billion INR | 4.21% |
| 2019 Q1 | 3.54 Billion INR | 8.98% |
| 2019 FY | 15.33 Billion INR | 24.34% |
| 2019 Q3 | 4.06 Billion INR | 9.91% |
| 2018 Q1 | 2.72 Billion INR | 2.59% |
| 2018 Q3 | 3.3 Billion INR | 8.22% |
| 2018 Q4 | 3.25 Billion INR | -1.46% |
| 2018 FY | 12.33 Billion INR | 33.03% |
| 2018 Q2 | 3.05 Billion INR | 12.12% |
| 2017 Q4 | 2.65 Billion INR | 11.84% |
| 2017 FY | 9.27 Billion INR | 133.72% |
| 2017 Q3 | 2.37 Billion INR | 7.55% |
| 2017 Q2 | 2.2 Billion INR | 8.43% |
| 2017 Q1 | 2.03 Billion INR | -2.8% |
| 2016 FY | 3.96 Billion INR | 25.79% |
| 2016 Q1 | 889.41 Million INR | -49.54% |
| 2016 Q2 | 899.4 Million INR | 1.12% |
| 2016 Q3 | 2.01 Billion INR | 123.53% |
| 2016 Q4 | 2.09 Billion INR | 4.13% |
| 2015 Q4 | 1.76 Billion INR | 128.59% |
| 2015 FY | 3.15 Billion INR | 36.34% |
| 2015 Q3 | 771.03 Million INR | -44.94% |
| 2015 Q2 | 1.4 Billion INR | 159.12% |
| 2015 Q1 | 540.39 Million INR | -22.69% |
| 2014 Q2 | 1.07 Billion INR | 106.76% |
| 2014 Q1 | 518.69 Million INR | -58.8% |
| 2014 FY | 2.31 Billion INR | -52.95% |
| 2014 Q4 | 699 Million INR | 21.13% |
| 2014 Q3 | 577.07 Million INR | -46.19% |
| 2013 Q1 | 1.19 Billion INR | -1.51% |
| 2013 Q2 | 1.24 Billion INR | 4.64% |
| 2013 Q3 | 1.18 Billion INR | -4.75% |
| 2013 FY | 4.91 Billion INR | 8.67% |
| 2013 Q4 | 1.25 Billion INR | 5.95% |
| 2012 Q1 | 1.05 Billion INR | 5.96% |
| 2012 Q2 | 1.1 Billion INR | 4.88% |
| 2012 FY | 4.52 Billion INR | 34.38% |
| 2012 Q4 | 1.21 Billion INR | 5.42% |
| 2012 Q3 | 1.14 Billion INR | 3.6% |
| 2011 Q3 | 803.41 Million INR | 3.47% |
| 2011 FY | 3.36 Billion INR | 290.46% |
| 2011 Q2 | 776.49 Million INR | 0.0% |
| 2011 Q4 | 997.45 Million INR | 24.15% |
| 2010 FY | 862.22 Million INR | 47.64% |
| 2009 FY | 584.02 Million INR | 27.34% |
| 2008 FY | 458.65 Million INR | 69.66% |
| 2007 FY | 270.33 Million INR | 49.04% |
| 2006 FY | 181.38 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 99.03% |
| Blue Jet Healthcare Limited | 531.85 Million INR | 25.372% |
| Concord Biotech Limited | 1.45 Billion INR | 72.809% |
| Dishman Carbogen Amcis Limited | 5.14 Billion INR | 92.289% |
| Jubilant Ingrevia Limited | 6.67 Billion INR | 94.049% |
| Lyka Labs Limited | 599.4 Million INR | 33.783% |
| Panacea Biotec Limited | 1.99 Billion INR | 80.109% |
| Piramal Pharma Limited | 19.91 Billion INR | 98.007% |
| SMS Lifesciences India Limited | 602.96 Million INR | 34.174% |
| Supriya Lifescience Limited | 1.08 Billion INR | 63.254% |
| Syngene International Limited | 5.99 Billion INR | 93.379% |
| Zota Health Care Limited | 457.83 Million INR | 13.307% |